patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug · small molecule

save

INLURIYO

updated 2mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

INLURIYO

generic

IMLUNESTRANT TOSYLATE

MOA

12.1 Mechanism of Action Imlunestrant is an estrogen receptor (ER) antagonist that binds to ERα. In vitro, imlunestrant induced degradation of ERα, leading to inhibition of ER-dependent gene transcription and cellular proliferation in ER+ breast cancer cells. Imlunestrant demonstrated in vitro and in vivo anti-tumor activity in ER+ breast cancer xenograft models, including models with ESR1 mutations.

indication

1 INDICATIONS AND USAGE INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. INLURIYO TM is an estrogen receptor antagonist indicated for: treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy ( 1 )

INLURIYO

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside